1. Home
  2. CUE vs HOWL Comparison

CUE vs HOWL Comparison

Compare CUE & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • HOWL
  • Stock Information
  • Founded
  • CUE 2014
  • HOWL 2017
  • Country
  • CUE United States
  • HOWL United States
  • Employees
  • CUE N/A
  • HOWL N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • HOWL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUE Health Care
  • HOWL Health Care
  • Exchange
  • CUE Nasdaq
  • HOWL Nasdaq
  • Market Cap
  • CUE 91.9M
  • HOWL 87.4M
  • IPO Year
  • CUE 2018
  • HOWL 2021
  • Fundamental
  • Price
  • CUE $1.26
  • HOWL $1.36
  • Analyst Decision
  • CUE Strong Buy
  • HOWL Strong Buy
  • Analyst Count
  • CUE 5
  • HOWL 2
  • Target Price
  • CUE $5.00
  • HOWL $9.50
  • AVG Volume (30 Days)
  • CUE 285.1K
  • HOWL 263.3K
  • Earning Date
  • CUE 03-10-2025
  • HOWL 03-06-2025
  • Dividend Yield
  • CUE N/A
  • HOWL N/A
  • EPS Growth
  • CUE N/A
  • HOWL N/A
  • EPS
  • CUE N/A
  • HOWL N/A
  • Revenue
  • CUE $9,532,000.00
  • HOWL $3,386,000.00
  • Revenue This Year
  • CUE $73.11
  • HOWL N/A
  • Revenue Next Year
  • CUE $11.02
  • HOWL $34.17
  • P/E Ratio
  • CUE N/A
  • HOWL N/A
  • Revenue Growth
  • CUE 149.53
  • HOWL N/A
  • 52 Week Low
  • CUE $0.45
  • HOWL $1.26
  • 52 Week High
  • CUE $2.58
  • HOWL $8.19
  • Technical
  • Relative Strength Index (RSI)
  • CUE 49.50
  • HOWL 41.40
  • Support Level
  • CUE $1.27
  • HOWL $1.26
  • Resistance Level
  • CUE $1.50
  • HOWL $1.45
  • Average True Range (ATR)
  • CUE 0.12
  • HOWL 0.09
  • MACD
  • CUE -0.01
  • HOWL 0.02
  • Stochastic Oscillator
  • CUE 53.73
  • HOWL 45.45

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Share on Social Networks: